Plus, news about Evotec, Bristol Myers Squibb and Precigen:
Roivant hints at another deal: The drugmaker may make an addition to its pipeline, saying it has plans for “unveiling one such program next month.” It has a successful history of forging deals, most notably creating a company with a former Pfizer asset that it quickly flipped in a $7.1 billion exit to Roche. The 2023 deal for Telavant led to another $110 million milestone payment this month, per Roivant’s Thursday quarterly earnings update.
Bavarian Nordic’s $156M deal: The US government is ordering more smallpox/mpox vaccines from the Danish company, which produces Jynneos. Earlier this week the Centers for Disease Control and Prevention issued another health alert for the mpox virus in the Democratic Republic of the Congo. The World Health Organization is also convening an emergency committee to decide if the outbreak should be considered a public health emergency of international concern.
Evotec gets $25M from Bristol Myers Squibb: Eight years into a neuroscience partnership, BMS is dishing out the payment to keep the research going.
Precigen prices $30M offering: A day after laying off more than 20% of its staff, the Maryland biotech said it will sell 35.29 million shares $PGEN at 85 cents apiece, which is below its closing price of $1.18 on Wednesday. Its stock was down 20% before Thursday’s opening bell.